Moreover, we show that the combination of BRAF and PIM inhibitors impedes tumor growth in vivo. Given that AKT and PIM kinases share signaling effectors, we finally explore the advantages of combining PI3K and PIM inhibitors in preclinical models of melanoma. This evidence concerns the gene PIM1 and melanoma.